Why the study?
Does increased apixaban exposure increase bleeding events in hospitalized adults with end-stage renal disease on hemodialysis?
Does increased apixaban exposure increase bleeding events in hospitalized adults with end-stage renal disease on hemodialysis?
In hospitalized patients with ESRD on hemodialysis, continuation of outpatient apixaban, higher daily doses, and more hemodialysis sessions are associated with significantly increased bleeding risk.
No takes yet. Share an insight, caveat, or question.
Certain factors may heighten bleeding risk with apixaban in ESRD on HD; leaves open need for prospective validation.
Steuber et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: